J Fernando Arevalo1, Andres F Lasave, Lihteh Wu, Mauricio Maia, Manuel Diaz-Llopis, Arturo A Alezzandrini, Miguel Brito. 1. *Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD; †Retina and Vitreous Service, Clínica Privada de Ojos, Mar del Plata, Argentina; ‡Instituto de Cirugia Ocular, San Jose, Costa Rica; §Departamento de Oftalmologia, Instituto da Visão, Universidade Federal de São Paulo, São Paulo, Brazil; ¶Consorcio Hospital, General Universitario de Valencia, Valencia, Spain; **Facultad de Medicina, OFTALMOS, Universidad de Buenos Aires, Buenos Aires, Argentina; and ††Instituto Docente de Especialidades Oftalmológicas (IDEO), Maracaibo, Venezuela.
Abstract
PURPOSE: To evaluate the effects of intravitreal bevacizumab (IVB) on retinal neovascularization in patients with proliferative diabetic retinopathy (PDR). METHODS: Retrospective multicenter interventional case series. A chart review was performed of 81 consecutive patients (97 eyes) with retinal neovascularization due to PDR, who received at least 1 IVB injection. RESULTS: The mean age of the patients was 55.6 ± 11.6 years. The mean number of IVB injections was 4 ± 2.5 injections (range, 1-8 injections) per eye. The mean interval between IVB applications was 3 ± 7 months. The mean duration of follow-up was 29.6 ± 2 months (range, 24-30 months). Best-corrected visual acuity and optical coherence tomography improved statistically significantly (P < 0.0001, both comparisons). Three eyes without previous panretinal photocoagulation ("naive" eyes) and with vitreous hemorrhage did not require vitreoretinal surgery. Five (5.2%) eyes with PDR progressed to tractional retinal detachment requiring vitrectomy. No systemic adverse events were noted. CONCLUSION: Intravitreal bevacizumab resulted in marked regression of retinal neovascularization in patients with PDR and previous panretinal photocoagulation. Intravitreal bevacizumab in naive eyes resulted in control or regression of 42.1% of eyes without adjunctive laser or vitrectomy during 24 months of follow-up. There were no safety concerns during the 2 years of follow-up of IVB for PDR.
PURPOSE: To evaluate the effects of intravitreal bevacizumab (IVB) on retinal neovascularization in patients with proliferative diabetic retinopathy (PDR). METHODS: Retrospective multicenter interventional case series. A chart review was performed of 81 consecutive patients (97 eyes) with retinal neovascularization due to PDR, who received at least 1 IVB injection. RESULTS: The mean age of the patients was 55.6 ± 11.6 years. The mean number of IVB injections was 4 ± 2.5 injections (range, 1-8 injections) per eye. The mean interval between IVB applications was 3 ± 7 months. The mean duration of follow-up was 29.6 ± 2 months (range, 24-30 months). Best-corrected visual acuity and optical coherence tomography improved statistically significantly (P < 0.0001, both comparisons). Three eyes without previous panretinal photocoagulation ("naive" eyes) and with vitreous hemorrhage did not require vitreoretinal surgery. Five (5.2%) eyes with PDR progressed to tractional retinal detachment requiring vitrectomy. No systemic adverse events were noted. CONCLUSION: Intravitreal bevacizumab resulted in marked regression of retinal neovascularization in patients with PDR and previous panretinal photocoagulation. Intravitreal bevacizumab in naive eyes resulted in control or regression of 42.1% of eyes without adjunctive laser or vitrectomy during 24 months of follow-up. There were no safety concerns during the 2 years of follow-up of IVB for PDR.
Authors: Rupin N Parikh; Anastasia Traband; Anton M Kolomeyer; Brian L VanderBeek; Benjamin J Kim; Albert M Maguire; Alexander J Brucker Journal: Am J Ophthalmol Date: 2017-01-24 Impact factor: 5.258
Authors: Suman K Paine; Lakshmi K Mondal; Prasanta K Borah; Chandra K Bhattacharya; Jagadish Mahanta Journal: Mol Vis Date: 2017-06-22 Impact factor: 2.367
Authors: Rebecca L Thomas; Stephen D Luzio; Rachel V North; Sanjiv Banerjee; Antra Zekite; Catey Bunce; David R Owens Journal: BMJ Open Date: 2017-07-18 Impact factor: 2.692
Authors: Luke Nicholson; Roxanne Crosby-Nwaobi; Joana C Vasconcelos; A Toby Prevost; Jayashree Ramu; Amy Riddell; James W Bainbridge; Philip G Hykin; Sobha Sivaprasad Journal: Invest Ophthalmol Vis Sci Date: 2018-08-01 Impact factor: 4.799